On the afternoon of November 21,2023,a significant event unfolded in Shanghai,as Wanbangde Pharmaceutical Holdings Group Co.,Ltd.(hereinafter referred to as "Wanbangde",stock code: 002082) hosted an institutional investor exchange meeting.The gathering brought together nearly 30 institutional investors,including representatives from leading firms such as Shenwan Securities,Huatai Securities,Hu'an Asset Management,Guocheng Investment,and Shengbang Private Equity.This event was a platform for Wanbangde to showcase its deep commitment and innovative achievements in the pharmaceutical and healthcare sectors,underlining the burgeoning interest from the investment community.

The meeting commenced with a heartfelt welcome from Wanbangde's Chairman,Zhao Shouming,who expressed sincere gratitude to all investors for their presence.He articulated the company's mission: "To drive the advancement of modern traditional Chinese medicine,chemical drugs,and high-end medical devices through innovation." His remarks emphasized Wanbangde's dedication to enhancing public health while also safeguarding shareholder returns,underscoring a dual commitment to societal benefit and business performance.

Following this,Liu Tongke,the company’s Secretary,presented a detailed overview of Wanbangde's business structure and historical development.Liu highlighted that since 2017,Wanbangde has effectively expanded its influence in the pharmaceutical industry through acquisitions and industrial upgrades,centering its operations around the pharmaceutical group.This strategic orientation has fostered the establishment of a comprehensive health industry ecosystem.Furthermore,Liu noted that the company operates four production bases both domestically and internationally,addressing various sectors including formulations,active pharmaceutical ingredients,orthopedic devices,and medical equipment.

Importantly,Huperzine A has gained significant international recognition in the pharmaceutical landscape,having received orphan drug designations from the U.S.Food and Drug Administration (FDA) for two products,one of which is classified as a treatment for rare diseases.Orphan drugs are particularly vital since they tackle medical conditions that are rare in occurrence.Due to the limited patient population,the development of drugs for rare diseases often comes with high costs and considerable risks,prompting various nations to establish robust support and regulatory frameworks.The FDA’s designation for Huperzine A underscores its unique advantages in treating specific rare diseases,marking a pivotal achievement in its clinical and preclinical journey.Such recognition reinforces the drug's safety,efficacy,and adherence to regulatory standards,thereby paving the way for further clinical trials,market launch,and ultimately benefiting a larger patient demographic.

During the interactive segment with investors,representatives of Wanbangde provided comprehensive answers to pressing market inquiries.Dr.Zhao Guanjia detailed the progression of Huperzine A,including the completion of initial clinical studies and the forthcoming launch of registration trials tailored to various indications.The distinct properties of Huperzine A,combined with a wealth of clinical data,suggest it could provide multiple benefits for patients.The development of sustained-release tablet formulations aims to offer more stable drug concentrations and improved safety,aspiring to achieve better clinical outcomes.The company aims to extend its benefits not only to patients in the moderate to severe stages of Alzheimer’s but also to those in earlier stages of cognitive decline,which could lead to unprecedented advancements in the treatment landscape.

Investors found the discussions to be enlightening,increasing their understanding of Wanbangde's innovative endeavors and investment potential.Chairman Zhao Shouming articulated the company’s forward-looking stance on appropriate financing strategies based on real business developments,which resonated well with the audience.

Market analysts observed that this exchange showcased Wanbangde's innovative prowess within the pharmaceutical and healthcare sectors,alongside significant research outcomes and promising international market prospects.The meeting solidified investor confidence in the company,establishing a robust foundation for its ongoing development in the healthcare industry.With the international recognition and market expansion of innovative drugs like Huperzine A,Wanbangde is positioning itself as a frontrunner in the realm of traditional Chinese medicine innovation,ushering in a new chapter for the global healthcare industry.